[go: up one dir, main page]

FR2819256B1 - Polypeptide induisant des anticorps neutralisant le vih - Google Patents

Polypeptide induisant des anticorps neutralisant le vih

Info

Publication number
FR2819256B1
FR2819256B1 FR0100141A FR0100141A FR2819256B1 FR 2819256 B1 FR2819256 B1 FR 2819256B1 FR 0100141 A FR0100141 A FR 0100141A FR 0100141 A FR0100141 A FR 0100141A FR 2819256 B1 FR2819256 B1 FR 2819256B1
Authority
FR
France
Prior art keywords
neutralizing antibodies
hiv neutralizing
inducing hiv
polypeptide inducing
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0100141A
Other languages
English (en)
Other versions
FR2819256A1 (fr
Inventor
Robert Brasseur
Benoit Charloteaux
Michel Chevalier
Habib Raphaelle El
Tino Krell
Regis Sodoyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0100141A priority Critical patent/FR2819256B1/fr
Application filed by Aventis Pasteur SA filed Critical Aventis Pasteur SA
Priority to AT02710945T priority patent/ATE324450T1/de
Priority to DE60210936T priority patent/DE60210936T2/de
Priority to PT02710945T priority patent/PT1368478E/pt
Priority to ES02710945T priority patent/ES2260416T3/es
Priority to PCT/FR2002/000031 priority patent/WO2002053587A2/fr
Priority to AU2002229850A priority patent/AU2002229850A1/en
Priority to CA2431881A priority patent/CA2431881C/fr
Priority to EP02710945A priority patent/EP1368478B1/fr
Priority to DK02710945T priority patent/DK1368478T3/da
Priority to US10/040,349 priority patent/US6861253B2/en
Publication of FR2819256A1 publication Critical patent/FR2819256A1/fr
Application granted granted Critical
Publication of FR2819256B1 publication Critical patent/FR2819256B1/fr
Priority to CY20061100881T priority patent/CY1105629T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR0100141A 2001-01-05 2001-01-05 Polypeptide induisant des anticorps neutralisant le vih Expired - Fee Related FR2819256B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR0100141A FR2819256B1 (fr) 2001-01-05 2001-01-05 Polypeptide induisant des anticorps neutralisant le vih
EP02710945A EP1368478B1 (fr) 2001-01-05 2002-01-04 Polypeptide induisant des anticorps neutralisant le vih
PT02710945T PT1368478E (pt) 2001-01-05 2002-01-04 Polipeptido indutor de anticorpos neutralizantes de vih
ES02710945T ES2260416T3 (es) 2001-01-05 2002-01-04 Polipeptido que induce anticuerpos que neutralizan el vih.
PCT/FR2002/000031 WO2002053587A2 (fr) 2001-01-05 2002-01-04 Polypeptide induisant des anticorps neutralisant le vih
AU2002229850A AU2002229850A1 (en) 2001-01-05 2002-01-04 Polypeptide inducing hiv-neutralising antibodies
AT02710945T ATE324450T1 (de) 2001-01-05 2002-01-04 Polypeptid, das neutralisierende antikörper gegen hiv induziert
DE60210936T DE60210936T2 (de) 2001-01-05 2002-01-04 Polypeptid, das neutralisierende antikörper gegen hiv induziert
DK02710945T DK1368478T3 (da) 2001-01-05 2002-01-04 Polypeptid, der fremkalder HIV-neutraliserende antistoffer
CA2431881A CA2431881C (fr) 2001-01-05 2002-01-04 Polypeptide induisant des anticorps neutralisant le vih
US10/040,349 US6861253B2 (en) 2001-01-05 2002-01-07 Polypeptide inducing antibodies neutralizing HIV
CY20061100881T CY1105629T1 (el) 2001-01-05 2006-06-28 Πολυπεπτιδιο που επαγει αντισωματα εξουδετερωσης του ηιv

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0100141A FR2819256B1 (fr) 2001-01-05 2001-01-05 Polypeptide induisant des anticorps neutralisant le vih

Publications (2)

Publication Number Publication Date
FR2819256A1 FR2819256A1 (fr) 2002-07-12
FR2819256B1 true FR2819256B1 (fr) 2004-04-30

Family

ID=8858558

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0100141A Expired - Fee Related FR2819256B1 (fr) 2001-01-05 2001-01-05 Polypeptide induisant des anticorps neutralisant le vih

Country Status (1)

Country Link
FR (1) FR2819256B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668201A2 (fr) * 2011-01-28 2013-12-04 Sanofi Pasteur SA Compositions immunogeniques comprenant des dérivés du polypeptide gp41 de hiv

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522448A (ja) * 1998-08-03 2002-07-23 ザ ユニバーシティー オブ モンタナ ウイルス疾患の予防および治療
JP2003529319A (ja) * 1999-01-08 2003-10-07 キャロル ディ． ウエイス， ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
ATE380822T1 (de) * 1999-12-16 2007-12-15 Whitehead Biomedical Inst Funf-helix protein

Also Published As

Publication number Publication date
FR2819256A1 (fr) 2002-07-12

Similar Documents

Publication Publication Date Title
EP1396500A4 (fr) Anticorps anti-trail-r
FR10C0050I2 (fr) Anticorps opgl
IS7133A (is) Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni
DK1414471T3 (da) Terapeutiske midler omfattende pro-apoptotiske proteiner
EP1423431A4 (fr) Anticorps anti-vla-1
EP1378520A4 (fr) Anticorps trispecifique monocatenaire cyclique
NO2012018I2 (no) Canakinumab eller direkte ekvivalenter derav
ATE553775T1 (de) Impstoffzusammesetzung
FR14C0007I1 (fr) Remodelage et glycoconjugaison de peptides
DE60119186D1 (de) Robotischer Laserzeiger
DE50202978D1 (de) Mittelkonsole
DK1427444T3 (da) West-nil-vaccine
EP1461077A4 (fr) Immunogene polyvalent
NO20033882D0 (no) Vaksine
DE50200615D1 (de) Geminitenside
DK1417234T3 (da) Rekombinante anti-plasmodium falciparum antistoffer
MA26998A1 (fr) Conjugues peg de hgt-nk4
DE50200250D1 (de) Geminitenside
EP1352072A4 (fr) Preparations de liberation d'acide nucleique
NO20016009L (no) Navigasjonskonsept
EP1359932A4 (fr) Polypeptides tip39
NO20032963D0 (no) Peptidforbindelser
FR2819256B1 (fr) Polypeptide induisant des anticorps neutralisant le vih
NO20024625D0 (no) Robotspill
DE50208010D1 (de) Alpha-hydroxysäureesterhaltige tensidzubereitungen

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20140930